Advance AI-powered Lung Cancer Diagnosis

0 users added it to the favorites
GE-announcement-lung-cancer-diagnosis
Credit: Clinician and research scientist evaluate lung nodules using Optellum software

Optellum and GE Healthcare signed a letter of intent to cooperatively develop and commercialize lung cancer diagnosis using AI. The companies will collaborate on the development and deployment of a diagnostic solution for lung cancer to improve early detection and patient outcomes. GE Healthcare will provide AI-based solutions to aid in the diagnosis of lung cancer.

The collaboration will help healthcare providers to determine the malignancy of lung nodules so they can expedite subsequent treatments.

Optellum’s Virtual Nodule Clinic is an AI-powered software that helps to identify and score malignancy probability of lung nodules. It can also be used to enhance the specificity and sensitivity of indeterminate nodule assessments.

This development will be a game changer for cancer diagnosis, as it will reduce the need to perform biopsies or surgical resection procedures, thereby accelerating diagnostic processes.

The Virtual Nodule Clinic is claimed to be the only AI-assisted diagnosis software approved by the US Food and Drug Administration (FDA) for early-stage lung cancer.

GE Healthcare and Optellum are collaborating to integrate AI solutions powered by GE Healthcare’s Edison platform into the Virtual Nodule Clinic. They will also work together to distribute the platform and bring Optellum’s Lung Cancer Prediction AI results into GE Healthcare’s existing workflow including Picture Archiving and Communication Systems (PACS) and Computed Tomography (CT).

GE Healthcare oncology solutions general manager Ben Newton said: “The precise diagnosis of lung cancer can greatly improve patient prognosis.

“The integration of imaging and medical device data from the Edison Platform with AI-enabled solutions like the one offered by the Optellum Virtual Nodule Clinic has the potential to streamline clinician workflows and advance our goal of making precision healthcare, taking the right action at the right time for every patient, at scale, as widely accessible as possible.”

Subscribe on LinkedIn
POST
SHARE
TWEET
PRINT
EMAIL
You May Also Like

Subscribe today and save your spot

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Do You Want To Boost Your Business?

drop us a line and keep in touch

article post CTA image

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.